About us
Senior Management
Zalán Péterfi
MD, PhD
ZALÁN IS THE CSO OF VASCULAR GROUP
With MD and PhD degrees from Semmelweis University, postdoctoral training at Harvard Medical School; Zalán is a Life-science focused manager, Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma, biotech and health industry.
He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact
Péter Puskás
MD, MBA
PÉTER IS THE CEO OF THE VASCULAR GROUP
Peter has a degree in Medicine (MD), a Masters Degree in Economics from Corvinus University, and also obtained his MBA degree at INSEAD, Singapore. He has been with McKinsey and Company for 10+ years where amongst others he supported multiple top tier pharma company across various topics including R&D, strategy, operations, business development and M&A.
He was the CEE regional leader of McKinsey’s healthcare and pharmaceutical practice before joining the Vascular Group in 2021.
NGS service management
Zoltán Bihari
PhD
ZOLTAN IS THE HEAD OF THE VASCULAR GENETIX NGS LABORATORY
Zoltán is a molecular biologist who earned his PhD in biotechnology from the University of Szeged. During his research career, he was the Head of Department for Metagenomics and then the Head of the GMP-certified Laboratory of Medicine at Bay Zoltán Nonprofit Ltd. for Applied Research. Formerly, Zoltán was the Field Application Specialist of Illumina NGS products at GeneTiCA Ltd.
His main areas of expertise are Next Generation Sequencing, metagenomics and human diagnostics. He has been coordinating R&D&I projects and supervising high-throughput NGS laboratories for 10 years. He is the Founder & CEO of an NGS service provider company, Xenovea Ltd.
Kristóf Árvai
PhD
KRISTÓF IS THE HEAD OF BIOINFORMATICS
Kristof is a molecular biologist and holds a PhD in clinical genetics from Semmelweis University.
He’s been working in the NGS field since the emergence of such technologies, from conducting hereditary cancer and oncology focused research to the complex diagnoses of rare diseases. He developed companion diagnostic procedures in close cooperation with the pharmaceutical industry.
For the past ten years Kristof was the head of a sequencing lab, and he is now leading the bioinformatics and clinical variant interpretation team.
Tamás Martonosi
MSc
TAMÁS IS THE OPERATIONS DIRECTOR OF VASCULAR GENETIX
Tamás has a degree in electrical engineering and more than 10 years of experience in the Hungarian healthcare industry.
He started his career as a software technology research and development engineer and worked for multinational and domestic companies in the sales of medical devices. His experience in public administration gives him a complex overview of the Hungarian healthcare sector.
Márton Megyeri
PhD, MBA
MÁRTON IS THE HEAD OF BUSINESS DEVELOPMENT
Marton is a bioengineer and holds a PhD in structural biochemistry and protein science. He was a postdoctoral researcher at the Weizmann Institute of Science in Israel. Alongside academic studies he earned an MBA degree.
With 9+ years of bio-pharmaceutical experience and 15+ years of academic track record he is able to integrate regulatory with process development, analytical development in order to deliver successful CMC for pharmaceutical and cell and gene therapy projects. He has participated in several BPD Tpye2 meetings with FDA and Scientific Advice with EMA and his team authored CMC sections of successful IND submissions. He scientifically supported business negotiations and participated on several in-licensing projects.
NGS application experts
János Kósa
PhD
JÁNOS IS THE HEAD OF CLINICAL APPLICATIONS
Janos is an experienced executive and laboratory manager with a demonstrated history of working in the governmental & private health care industry. Molecular Biologist, having a Ph.D. degree from Semmelweis University. Currently, besides professionally guiding Vascular Laboratory, he is a research fellow at Semmelweis University.
His main scientific interests include the different genetic diseases’ early and fast diagnostics and supporting therapeutic decisions with genetic diagnostics. He has substantial experience in developing and running CE-IVD techniques. Skilled in oncology, molecular biology, NGS, biotechnology, and high throughput screening. He has published 100+ peer-reviewed papers, with more than 180 IF.
Prof. Péter Lakatos
MD, DSc
PÉTER IS THE MEDICAL DIRECTOR
After studies in biology and chemistry, Dr. Peter Lakatos finished medical school at the Semmelweis University, Budapest, in 1981. Currently, he is a full professor of medicine and endocrinology at the Department of Medicine and Oncology, as well as head of the Clinical Research Laboratory, at the Semmelweis University.
Dr. Lakatos and his research group have actively participated in the development and introduction of biochemical and densitometric methods in the management and research of osteoporosis. In the 80’s, he was among first to develop a commercial osteocalcin radioimmunoassay.
During the last two decades, his major interest has been in the genetic background of metabolic bone diseases as well as thyroid cancer.
He has authored more than 400 full length scientific articles and book chapters. Amongst other posts, Dr. Lakatos has acted as the President of the Hungarian Society for Osteoporosis and Osteoarthrology and was a board member of the European Society for Calcified Tissues.
János Molnár
MSc
Janos is an experienced bioinformatician involved in multiple next-generation sequencing (NGS) projects. He has more than ten years of experience in this field. His main area of interest is identification and interpretation of genetic mutations especially in clinical data and in transmembrane proteins. He participated in Hungary’s first agrigenomics project, where he developed a Mangalica specific real-time PCR diagnostic method based on whole genomic data. He is proud that he could work on NGS data derived from the bones of Bela III of Hungary. He has 20 scientific publications in international papers with more than 450 citations and a book chapter.
